Biomarkers and Next Generation Sequencing in Chronic Kidney Disease

Crossmark: check for updates

Authors

  • Ying Shi, MD Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St. Leonards, NSW 2006, Australia
  • Hao Yi, MD Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St. Leonards, NSW 2006, Australia
  • Chunling Huang, PhD Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St. Leonards, NSW 2006, Australia
  • Carol A. Pollock, MD Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St. Leonards, NSW 2006, Australia
  • Xin-Ming Chen, PhD Kolling Institute of Medical Research, Royal North Shore Hospital, University of Sydney, St. Leonards, NSW 2006, Australia

DOI:

https://doi.org/10.17140/NPOJ-2-115

Keywords:

personalized, therapeutic, sequencing

Abstract

Biomarkers are valuable for early diagnosis, predicting prognosis and monitoring therapeutic
efficacy in medicine, and particularly important in ‘personalized medicine’.1 Next generation
sequencing technologies and their application in human diseases to foster human healthcare
and personalized medicine have been recognized.2
To date, reliable biomarkers for chronic kidney disease (CKD) are not available in clinic and the application of next generation sequencing
technologies in CKD has not been well studied.

References

Suh KS. Discovery of novel biomarkers for the development of personalized medicine. Translational Medicine. 2012; S1: e1-e2.

Rabbani B, Nakaoka H, Akhondzadeh S, Tekin M, Mahdieh N. Next generation sequencing: Implications in personalized medicine and pharmacogenomics. Mol Biosyst. 2016; 12(6): 1818-1830. doi: 10.1039/c6mb00115g

Wong MG, Pollock CA. Biomarkers in kidney fibrosis: Are they useful? Kidney Int Suppl (2011). 2014; 4(1): 79-83. doi: 10.1038/kisup.2014.15

Wasung ME, Chawla LS, Madero M. Biomarkers of renal function, which and when? Clin Chim Acta. 2015; 438: 350-357. doi: 10.1016/j.cca.2014.08.039

Breit M, Weinberger KM. Metabolic biomarkers for chronic kidney disease. Arch Biochem Biophys. 2016; 589: 62-80. doi: 10.1016/j.abb.2015.07.018

Levey AS, Becker C, Inker LA. Glomerular filtration rate and albuminuria for detection and staging of acute and chronic kid-ney disease in adults: A systematic review. JAMA. 2015; 313(8): 837-846. doi: 10.1001/jama.2015.0602

Lopez-Giacoman S, Madero M. Biomarkers in chronic kid-ney disease, from kidney function to kidney damage. World J Nephrol. 2015; 4(1): 57-73. doi: 10.5527/wjn.v4.i1.57

Ye L, Mao W. Metabonomic biomarkers for risk factors of chronic kidney disease. Int Urol Nephrol. 2016; 48: 547-552. doi: 10.1007/s11255-016-1239-6

Simpson K, Wonnacott A, Fraser DJ, Bowen T. MicroRNAs in diabetic nephropathy: From biomarkers to therapy. Curr Diab Rep. 2016; 16: 35. doi: 10.1007/s11892-016-0724-8

Gohda T, Niewczas MA, Ficociello LH, et al. Circulat-ing TNF receptors 1 and 2 predict stage 3 CKD in type 1 di-abetes. J Am Soc Nephrol. 2012; 23: 516-524. doi: 10.1681/ ASN.2011060628

Wong MG, Perkovic V, Woodward M, et al. Circulating bone morphogenetic protein-7 and transforming growth factor-beta1 are better predictors of renal end points in patients with type 2 diabetes mellitus. Kidney Int. 2013; 83: 278-284. doi: 10.1038/ ki.2012.383

Cayer D, Nazor KL, Schork NJ. Mission critical: The need for proteomics in the era of next-generation sequencing and precision medicine. Hum Mol Genet. 2016. doi: 10.1093/hmg/ ddw214

Metzker ML. Sequencing technologies - the next generation. Nat Rev Genet. 2010; 11: 31-46. doi: 10.1038/nrg2626

Trujillano D, Bullich G, Ossowski S, et al. Diagnosis of auto-somal dominant polycystic kidney disease using efficient PKD1 and PKD2 targeted next-generation sequencing. Mol Genet Ge-nomic Med. 2014; 2: 412-421. doi: 10.1002/mgg3.82

Zhan Y, Guo W, Zhang Y, Wang Q, Xu X-J, Zhu L. A Five-Gene signature predicts prognosis in patients with kidney re-nal clear cell carcinoma. Comput Math Methods Med. 2015; 842784: 7. doi: 10.1155/2015/842784

Westland R, Sanna-Cherchi S. Recessive mutations in CA-KUT and VACTERL association. Kidney Int. 2014; 85: 1253- 1255. doi: 10.1038/ki.2013.495

Wang JJ, Mao JH. The etiology of congenital nephrotic syn-drome: Current status and challenges. World J Pediatr. 2016; 12(2): 149-158. doi: 10.1007/s12519-016-0009-y

Nassirpour R, Mathur S, Gosink MM, et al. Identification of tubular injury microRNA biomarkers in urine: Comparison of next-generation sequencing and qPCR-based profiling plat-forms. BMC Genomics. 2014; 15: 485. doi: 10.1186/1471-2164- 15-485

Tavira B, Gómez J, Diaz-Corte C, et al. ABCB1 (MDR-1) pharmacogenetics of tacrolimus in renal transplanted patients: A next generation sequencing approach. Clin Chem Lab Med. 2015; 53: 1515-1519. doi: 10.1515/cclm-2014-1195

Sahoo MK, Tan SK, Chen SF, et al. Limited variation in BK virus T-cell epitopes revealed by next-generation sequencing. J Clin Microbiol. 2015; 53: 3226-3233. doi: 10.1128/JCM.01385-

Ball MW, Gorin MA, Guner G, et al. Circulating tumor DNA as a marker of therapeutic response in patients with renal cell carcinoma: A pilot study. Clin Genitourin Cancer. 2016. doi: 10.1016/j.clgc.2016.03.019

Brennan EP, Morine MJ, Walsh DW, et al. Next-generation sequencing identifies TGF-beta1-associated gene expression profiles in renal epithelial cells reiterated in human diabetic ne-Nephrol Open J phropathy. Biochim Biophys Acta. 2012; 1822: 589-599. doi: 10.1016/j.bbadis.2012.01.008

Albert GI, Schell C, Kirschner KM, et al. The GYF domain protein CD2BP2 is critical for embryogenesis and podocyte function. J Mol Cell Biol. 2015; 7(5): 402-414. doi: 10.1093/ jmcb/mjv039

Yang W, Yoshigoe K, Qin X, et al. Identification of genes and pathways involved in kidney renal clear cell car-cinoma. BMC Bioinformatics. 2014; 15(Suppl 17): S2. doi: 10.1186/1471-2105-15-S17-S2

Downloads

Published

2016-08-10

How to Cite

Ying Shi, MD, Hao Yi, MD, Chunling Huang, PhD, Carol A. Pollock, MD, & Xin-Ming Chen, PhD. (2016). Biomarkers and Next Generation Sequencing in Chronic Kidney Disease. Nephrology, 2(1), 23–25. https://doi.org/10.17140/NPOJ-2-115

Issue

Volume 2 Issue 1 2016

Section

Articles

License

Creative Commons License

This work is licensed under a Creative Commons Attribution 4.0 International License.

All content published in Nephrology (NOJ) is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This license allows anyone to copy, distribute, transmit, and adapt the work — including for commercial purposes — provided appropriate credit is given to the original author(s) and source.